Severe ICANS after CAR T-cell therapy and assessment of prevention with levetiracetam for seizure prophylaxis following CAR T-cell for DLBCL & PMBCL in Europe: a survey on behalf of the Cellular Therapy & Immunobiology Working Party (CTIWP) of the EBMT

This publication has 10 references indexed in Scilit:

• Current understanding and management of CAR T cell-associated toxicities
  Nature Reviews Clinical Oncology, 2024
• How I treat unique and difficult to manage cases of CAR T-cell therapy associated neurotoxicity
  Blood, 2023
• Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)
  Annals of Oncology, 2022
• Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy
  Nature Reviews Immunology, 2021
• Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
  The Lancet, 2020
• KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
  New England Journal of Medicine, 2020
• How I treat adverse effects of CAR-T cell therapy
  ESMO Open, 2020
• Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
  New England Journal of Medicine, 2019
• Chimeric Antigen Receptor Therapy
  New England Journal of Medicine, 2018
• Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
  New England Journal of Medicine, 2017